BOTHELL, Wash., April 30, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will report its first quarter 2018 financial and operating results after the close of U.S. financial markets on Tuesday, May 8, 2018. Alder management will host a conference call and live audio webcast with accompanying slides to discuss the results and provide a general business update at 5:00 p.m. ET the same day.
The live call may be accessed by dialing (877) 430-4657 for domestic callers or (484) 756-4339 for international callers and providing conference ID number 1767109. The webcast and accompanying slides can be accessed from the Events & Presentations page in the Investors section of Alder's website at www.alderbio.com and will be available for replay following the call for at least 30 days.
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, please visit www.alderbio.com.
Investor Relations Contacts:
Vice President, Corporate Strategy
Alder Biopharmaceuticals, Inc.
Stern Investor Relations, Inc.
Andy Brimmer / Aura Reinhard / Trevor Gibbons
Joele Frank, Wilkinson Brimmer Katcher
Source: Alder BioPharmaceuticals, Inc.